Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board grew its position in Becton, Dickinson and Company (NYSE:BDX) by 15.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,193 shares of the medical instruments supplier’s stock after purchasing an additional 37,851 shares during the period. Canada Pension Plan Investment Board owned approximately 0.10% of Becton, Dickinson and Company worth $69,334,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Ontario Teachers Pension Plan Board lifted its position in Becton, Dickinson and Company by 3.8% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after acquiring an additional 68,509 shares in the last quarter. Jennison Associates LLC lifted its position in Becton, Dickinson and Company by 4.9% during the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after acquiring an additional 18,786 shares in the last quarter. Sapient Capital LLC acquired a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $1,295,000. Norden Group LLC lifted its position in Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after acquiring an additional 49,559 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $11,998,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $237.30 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $286.46. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $68.58 billion, a price-to-earnings ratio of 52.27, a price-to-earnings-growth ratio of 2.08 and a beta of 0.42. The business has a 50 day simple moving average of $232.24 and a 200-day simple moving average of $236.16.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.86 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.60%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Insider Buying and Selling

In related news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock worth $2,033,381 in the last three months. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on BDX. Evercore ISI cut their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Barclays upped their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday. Citigroup cut their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $280.13.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.